Notably, in phase II clinical trial on Tadekinig-α, 50% of the AOSD cohort reached normal body temperature and reduced C-reactive protein (CRP) levels within 3 weeks under treatment, confirming the neutralization effect of the free bioactive IL-18 [129]. Here, IL18 is linked to adult-onset Still disease.